$XNCR

RANIERI RICHARD J sold $67K of XNCR

RANIERI RICHARD J sold 5,474 shares of Xencor Inc (XNCR) at $12.31 on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RANIERI RICHARD J
Published Jun 17, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$XNCR
Neutral
high confidence
Mentioned
$XNCR
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XNCRNeutralLow
01

Why it matters

Because the transaction is pre-arranged and lacks any accompanying fundamental update, the likely impact is sentiment-only and should be small unless the pattern of insider activity is unusual.

02

Market read

A routine director sale under 10b5-1 provides limited incremental trading information for Xencor.

03

What to watch

The article provides only the sale details; it does not indicate whether the director’s remaining holdings changed materially over time or whether there were concurrent buys.

Relevance 2/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-17 (sale dated 2026-06-15)

Background

The filing is an SEC Form 4 insider transaction for Xencor, showing a director’s open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$XNCRNeutralHigh confidence
Context

Xencor director Richard J Ranieri filed a Form 4 selling 5,474 shares at $12.31 on 2026-06-15 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should fade unless accompanied by other company-specific catalysts.

Evidence & confidence

The disclosure is a routine director open-market sale with explicit 10b5-1 pre-arrangement; no new operational, financial, or regulatory facts are provided.

Market effects

No sector-level read-through; this is an individual insider transaction without new company fundamentals.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, traders sometimes interpret repeated insider selling as a mild caution signal—watch for follow-on sales or other negative disclosures.

Key entities

  • Xencor Inc

    Subject of the Form 4 insider sale disclosure.

  • RANIERI RICHARD J

    Director who sold 5,474 shares at $12.31 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$XNCRHighAI 8/10

Truist raises Xencor stock price target on kidney cancer drug data

Truist Securities raised its price target for Xencor (XNCR) to $40 from $29, citing positive clinical data for XmAb819 in kidney cancer. The stock has gained 17% in a week. Truist increased peak sales estimates to $1.1B and success probability to 35%. XNCR's market cap is $2.18B, with a 91% YTD return. Other analysts also upgraded price targets based on ESMO conference data.